Contact Information: For More Information, Contact: James E. Fickenscher CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 William Q. Sargent, Jr. V.P., IR Auxilium Pharmaceuticals, Inc. (484) 321-5900
Auxilium Pharmaceuticals to Present at the Piper Jaffray 20th Annual Healthcare Conference
| Source: Auxilium Pharmaceuticals, Inc.
MALVERN, PA--(Marketwire - November 18, 2008) - Auxilium Pharmaceuticals, Inc. (NASDAQ : AUXL )
today announced that executive management will participate in the Piper
Jaffray Healthcare Conference to be held December 2 - 3 at The New York
Palace. Mr. Armando Anido, Chief Executive Officer and President, is
scheduled to present an overview of the Company and its product pipeline at
9:30 a.m. EST on Wednesday, December 3, 2008.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets
Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism
through its approximately 190-person sales and marketing team. Auxilium
has five projects in clinical development. XIAFLEX™ (clostridial
collagenase for injection), formerly referred to as AA4500, is in phase
III of development for the treatment of Dupuytren's contracture and is in
phase II of development for the treatment of Peyronie's disease and Frozen
Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film
product candidate for the treatment of overactive bladder (AA4010) is in
phase I of development. The Company is currently seeking a partner to
further develop this product candidate. Auxilium also has one pain product
(fentanyl) using its transmucosal film delivery system in phase I of
development. Auxilium has rights to seven additional pain products and
products for hormone replacement and urologic disease using its
transmucosal film delivery system. Auxilium also has options to all
indications using XIAFLEX for non-topical formulations. For additional
information, visit http://www.auxilium.com.
SAFE HARBOR STATEMENT
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the Piper Jaffray 20th
Annual Healthcare Conference, and the Company's products in development
for Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome,
overactive bladder, pain, hormone replacement and urologic disease. All
statements other than statements of historical facts contained in this
release, including but not limited to, statements regarding future
expectations, plans and prospects for the Company, statements regarding
forward-looking financial information and other statements containing the
words "believe," "may," "could," "will," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "expect," and similar
expressions, as they relate to the Company, constitute forward-looking
statements. Actual results may differ materially from those reflected in
these forward-looking statements due to various factors, including general
financial, economic, regulatory and political conditions affecting the
biotechnology and pharmaceutical industries and those discussed in the
Company's Annual Report on Form 10-K for the year ended December 31, 2007
and the Company's Quarterly Report on Form 10-Q for the period ended
September 30, 2008 under the heading "Risk Factors," which are on file with
the Securities and Exchange Commission (the "SEC") and may be accessed
electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of the Company's home page on the Internet
at http://www.auxilium.com under the heading "Investor Relations -- SEC
Filings." There may be additional risks that the Company does not presently
know or that the Company currently believes are immaterial which could also
cause actual results to differ from those contained in the forward-looking
statements. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.